Statements (20)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:acquisitionYear |
2023
|
| gptkbp:CEO |
gptkb:Ken_Song
|
| gptkbp:focusesOn |
oncology
radiopharmaceuticals |
| gptkbp:foundedYear |
2020
|
| gptkbp:founder |
gptkb:Ken_Song
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
RayzeBio
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
RZ-101
RZ-301 |
| gptkbp:publiclyTraded |
yes
|
| gptkbp:specializesIn |
targeted radiopharmaceutical therapeutics
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:stockSymbol |
RYZB
|
| gptkbp:website |
https://www.rayzebio.com/
|
| gptkbp:bfsParent |
gptkb:Versant_Ventures
|
| gptkbp:bfsLayer |
7
|